ArticleOncoTargets and therapy2019
miR-522-3p Promotes Osteosarcoma Cell Growth By Regulating Glucose Uptake And GLUT1 Expression.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Pan-Cancer Analysis of microRNA Tissue Specificity and Its Association with Dysregulation.International journal of molecular sciences · 2026Article
- MCellular oncology (Dordrecht, Netherlands) · 2026Article
- Curcumin Inhibits the Development of Pancreatic Cancer by Targeting the circ_0079440/miR-522-3p/EIF4A1 Pathway.Cell biochemistry and biophysics · 2025Article
- Reprogramming of glucose metabolism: Metabolic alterations in the progression of osteosarcoma.Journal of bone oncology · 2024Review
- Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.Frontiers in endocrinology · 2023Review
- The roles of glycolysis in osteosarcoma.Frontiers in pharmacology · 2022Review
- KLK6 mediates stemness and metabolism of gastric carcinoma cells via the PI3K/AKT/mTOR signaling pathway.Oncology letters · 2021Article
- LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.Bioengineered · 2021Article
- Decarboxylated osteocalcin, a possible drug for type 2 diabetes, triggers glucose uptake in MG63 cells.World journal of diabetes · 2021Article
- Targeting of ΔNp63α by miR-522 promotes the migration of breast epithelial cells.FEBS open bio · 2021Article
- Review
- Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism.The EPMA journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn a recent study, Kang et al reported a novel miRNA named miR-522-3p with critical roles in phagocytosis, in which GLUT1 played a critical role, indicating the possible interactions between them. This study aimed to investigate the role of miR-522-3p in osteosarcoma (OS).
methodsGene expression was analyzed by qPCR and Western blot. Overexpression experiments were performed to analyze gene interactions. Glucose uptake assay was performed to analyze the effects of glucose uptake in cells. CCK-8 assay was used to analyze cell proliferation.
resultsWe found that miR-522-3p and GLUT1 were both upregulated in OS and positively correlated. Follow-up showed that high levels of miR-522-3p expression predicted poor survival. In OS cells, miR-522-3p overexpression led to upregulated GLUT1 expression and increase glucose uptake. Analysis of cell proliferation assay showed that overexpression of miR-522-3p and GLUT1 led to increased cell proliferate rates. In addition, GLUT1 siRNA silencing resulted in reduced effects of miR-522-3p overexpression.
conclusionMiR-522-3p promotes OS cell growth through reprogramming glucose metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.